Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA clears Zyrtec line extension

This article was originally published in The Tan Sheet

Executive Summary

McNeil Consumer Healthcare gains regulatory approval for Zyrtec Allergy orally disintegrating tablets (cetirizine 10 mg). In a Sept. 3 1letter, FDA's Division of Nonprescription Clinical Evaluation green-lights McNeil's new drug application, submitted in November 2009, for 6-, 12-, 24- and 66-count cartons of the OTC. The Johnson & Johnson subsidiary has fulfilled the pediatric study requirements for the Zyrtec extension, FDA adds. J&J/McNeil declined to comment on when the tablets will launch. With generics readily available, Zyrtec and other brands seek innovative delivery formats to stay a step ahead of private label (2"The Tan Sheet" Oct. 6, 2008)

You may also be interested in...

Fending Off Private Label Competition: Innovation Is Key

Innovative drug delivery, claims and packaging are keys to defending name brands from private label competition as consumers grow increasingly price sensitive

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Shuttered US Supplement Firm Meets Recall Deadline, But Schumer Says FDA Late Cleaning Up Industry

While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts